Related Experiment Video
Updated: Jan 10, 2026

Extraction and Analysis of Taiwanese Green Propolis
Published on: January 7, 2019
Hypoglycemic diterpenoids from Tinospora crispa.
Sio-Hong Lam1, Chi-Tun Ruan, Po-Hung Hsieh
1School of Pharmacy, College of Medicine, National Taiwan University, 1 Jen-Ai Road, Taipei 10051, Taiwan, Republic of China.
Tinospora crispa yielded new diterpenoids with significant hypoglycemic activity. Borapetosides A-C effectively lowered plasma glucose in mice by enhancing glucose utilization and reducing hepatic gluconeogenesis.
Area of Science:
- Phytochemistry
- Pharmacology
- Endocrinology
Background:
- Tinospora crispa is a medicinal plant with a history of traditional use.
- Diterpenoids are a class of natural products with diverse biological activities.
- Understanding the chemical constituents and pharmacological effects of Tinospora crispa is crucial for its medicinal applications.
Purpose of the Study:
- To isolate and characterize new diterpenoids from Tinospora crispa.
- To investigate the in vivo hypoglycemic activities of isolated compounds.
- To elucidate the mechanism of action for the observed hypoglycemic effects.
Main Methods:
- Extraction of Tinospora crispa vines using ethanol.
- Isolation and purification of compounds using chromatographic techniques.
- Structure elucidation using spectroscopic analyses (NMR, MS).
- In vivo evaluation of hypoglycemic activity in normal and diabetic mice models.
- Mechanistic studies involving glucose utilization and hepatic gluconeogenesis.
Main Results:
- Three new diterpenoids (2-O-lactoylborapetoside B, 6'-O-lactoylborapetoside B, tinocrispol A) and nine known diterpenoids were isolated.
- The stereochemistry of the C-6 glucosyloxy group in borapetoside C was revised to alpha.
- Borapetosides A-C demonstrated significant in vivo hypoglycemic activity.
- Borapetoside C administration led to increased glucose utilization and reduced hepatic gluconeogenesis.
Conclusions:
- Tinospora crispa is a rich source of bioactive diterpenoids.
- Borapetosides A-C, particularly borapetoside C, exhibit potent hypoglycemic effects.
- The hypoglycemic mechanism of borapetoside C involves peripheral glucose uptake and reduced hepatic glucose production, supporting its therapeutic potential for diabetes.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Glinides
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: Sulfonylureas

